| Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification P le Coutre, E Tassi, M Varella-Garcia, R Barni, L Mologni, G Cabrita, ... Blood, The Journal of the American Society of Hematology 95 (5), 1758-1766, 2000 | 704 | 2000 |
| In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor P Le Coutre, L Mologni, L Cleris, E Marchesi, E Buchdunger, R Giardini, ... Journal of the National Cancer Institute 91 (2), 163-168, 1999 | 494 | 1999 |
| Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis C Gambacorti-Passerini, P Le Coutre, L Mologni, M Fanelli, C Bertazzoli, ... Blood Cells, Molecules, and Diseases 23 (3), 380-394, 1997 | 456 | 1997 |
| Recurrent SETBP1 mutations in atypical chronic myeloid leukemia R Piazza, S Valletta, N Winkelmann, S Redaelli, R Spinelli, A Pirola, ... Nature genetics 45 (1), 18-24, 2013 | 421 | 2013 |
| Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase–positive lymphoma patients C Gambacorti Passerini, F Farina, A Stasia, S Redaelli, M Ceccon, ... Journal of the National Cancer Institute 106 (2), djt378, 2014 | 310 | 2014 |
| Entrectinib, a Pan–TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications E Ardini, M Menichincheri, P Banfi, R Bosotti, C De Ponti, R Pulci, ... Molecular cancer therapeutics 15 (4), 628-639, 2016 | 294 | 2016 |
| Bcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylation AML Coluccia, A Vacca, M Dunach, L Mologni, S Redaelli, VH Bustos, ... The EMBO journal 26 (5), 1456-1466, 2007 | 288 | 2007 |
| BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells E Sala, L Mologni, S Truffa, C Gaetano, GE Bollag, ... Molecular Cancer Research 6 (5), 751-759, 2008 | 256 | 2008 |
| Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases M Gianni, I Ponzanelli, L Mologni, U Reichert, A Rambaldi, M Terao, ... Cell Death & Differentiation 7 (5), 447-460, 2000 | 133 | 2000 |
| Three novel patient‐derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors S Redaelli, L Mologni, R Rostagno, R Piazza, V Magistroni, M Ceccon, ... American journal of hematology 87 (11), E125, 2012 | 126 | 2012 |
| Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting I Plaza-Menacho, L Mologni, E Sala, C Gambacorti-Passerini, AI Magee, ... Journal of Biological Chemistry 282 (40), 29230-29240, 2007 | 118 | 2007 |
| Mechanisms of RET signaling in cancer: current and future implications for targeted therapy I Plaza-Menacho, L Mologni, NQ McDonald Cellular signalling 26 (8), 1743-1752, 2014 | 115 | 2014 |
| Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase L Mologni, S Redaelli, A Morandi, I Plaza-Menacho, ... Molecular and cellular endocrinology 377 (1-2), 1-6, 2013 | 112 | 2013 |
| In vitro transcription and translation inhibition by anti-promyelocytic leukemia (PML)/retinoic acid receptor alpha and anti-PML peptide nucleic acid C Gambacorti-Passerini, L Mologni, C Bertazzoli, P Le Coutre, E Marchesi, ... | 108 | 1996 |
| Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors M Ceccon, L Mologni, W Bisson, L Scapozza, C Gambacorti-Passerini Molecular Cancer Research 11 (2), 122-132, 2013 | 104 | 2013 |
| The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid … L Mologni, I Ponzanelli, F Bresciani, G Sardiello, D Bergamaschi, ... Blood, The Journal of the American Society of Hematology 93 (3), 1045-1061, 1999 | 99 | 1999 |
| Lorlatinib treatment elicits multiple on-and off-target mechanisms of resistance in ALK-driven cancer S Redaelli, M Ceccon, M Zappa, GG Sharma, C Mastini, M Mauri, ... Cancer research 78 (24), 6866-6880, 2018 | 93 | 2018 |
| Activity of second‐generation ALK inhibitors against crizotinib‐resistant mutants in an NPM‐ALK model compared to EML4‐ALK D Fontana, M Ceccon, C Gambacorti‐Passerini, L Mologni Cancer medicine 4 (7), 953-965, 2015 | 93 | 2015 |
| Synthesis, structure–activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors L Mologni, R Rostagno, S Brussolo, PP Knowles, S Kjaer, J Murray-Rust, ... Bioorganic & medicinal chemistry 18 (4), 1482-1496, 2010 | 88 | 2010 |
| Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity A Donella-Deana, O Marin, L Cesaro, RH Gunby, A Ferrarese, ... Biochemistry 44 (23), 8533-8542, 2005 | 88 | 2005 |
